TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06975618: A Phase I/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CYH33 (a Selective PI3Kα Inhibitor) in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PI

Sponsor: Haihe Biopharma Co., Ltd. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 141 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,712,740

Rescue Site Savings

+$3,104,200

Unlock Full NCT06975618 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06975618 Rescue Dossier →